Guillain-Barré syndrome following H1N1 immunization in a pediatric patient

Annals of Pharmacotherapy

Volumn 44, Issue 7-8, 2010, Pages 1330-1333

  Tremblay, Marie Eve ^a   Closon, Aurélie ^a   D'Anjou, Guy ^a   Bussières, Jean François ^a  

^a UNIVERSITY OF MONTREAL   (Canada)

Author keywords

Arepanrix; Guillain Barr syndrome; H1N1 vaccine

Indexed keywords

AREPANRIX; IBUPROFEN; IMMUNOGLOBULIN; INFLUENZA VACCINE; PARACETAMOL; UNCLASSIFIED DRUG;

ARTICLE; CASE REPORT; CEREBROSPINAL FLUID ANALYSIS; CHILD; CLINICAL FEATURE; FACIAL NERVE PARALYSIS; GUILLAIN BARRE SYNDROME; HEADACHE; HUMAN; INFLUENZA A (H1N1); INFLUENZA VACCINATION; INFLUENZA VIRUS A H1N1; LEG PAIN; MALE; NAUSEA; NECK PAIN; PAIN; PARESTHESIA; PRIORITY JOURNAL; SCHOOL CHILD; VOMITING; GUILLAIN-BARRE SYNDROME; INFLUENZA, HUMAN;

CHILD; GUILLAIN-BARRE SYNDROME; HUMANS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN; MALE;

EID: 77954569608     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1P078     Document Type: Article

References (28)

1. Hughes RA, Rees JH. Clinical and epidemiologic features of Guillain-Barré syndrome. J Infect Dis 1997;176:S92-8.
2. McGrogan A, Madle GC, Seaman HE, de Vries CS. The epidemiology of Guillain-Barré syndrome worldwide. A systematic literature review. Neuroepidemiology 2009;32:150-63.
3. Evans OB, Vedanarayanan V. Guillain-Barré syndrome. Pediatr Rev 1997;18:10-6.
4. Haber P, Sejvar J, Mikaeloff Y, DeStefano F. Vaccines and Guillain-Barré syndrome. Drug Saf 2009;32:309-23.
5. Schonberger LB, Bergman DJ, Sullivan-Bolyai JZ, et al. Guillain-Barré syndrome following vaccination in the National Influenza Immunization Program, United States, 1976-1977. Am J Epidemiol 1979;110:105-23.
6. Institute of Medicine. Immunization safety review. Influenza vaccines and neurological complications. Washington, DC: National Academies Press, 2003.
7. Kaplan JE, Katona P, Hurwitz ES, Schonberger LB. Guillain-Barré syndrome in the United States, 1979-1980 and 1980-1981. Lack of an association with influenza vaccination. JAMA 1982;248:698-700.
8. Evans D, Cauchemez S, Hayden FG. "Prepandemic" immunization for novel influenza viruses, "swine flu" vaccine, Guillain-Barré syndrome, and the detection of rare severe adverse events. J Infect Dis 2009;200:321-8.
9. Safety of influenza A (H1N1) 2009 monavalent vaccines. Centers for Disease Control and Prevention. MMWR Morb Mortal Wkly Rep 2009;58:1351-6.
10. Public Health Agency of Canada. H1N1 Flu virus - H1N1 flu vaccine information - vaccine surveillance report - adverse events following immunization. www.phac-aspc.gc.ca/alert-alerte/h1n1/vacc/addeve-fra.php (accessed 2010 May 10).
11. World Health Organization. Programmes and projects - global alert and response (GAR) - diseases covered by GAR - pandemic (H1N1)2009 - briefing notes. www.who.int/csr/disease/swineflu/notes/briefing-20091119/en/ (accessed 2010 Jan 25).
12. Landry O. Note sur la paralysie ascendante aigue. Gazette Hebdomadaire de Médecine et de chirurgie 1859;6:472-4, 486-8.
13. Guillain G, Barré JA, Strohl A. Sur un syndrome de radiculo-névrite hyperalbuminose du liquide céphalorachidien sans réaction cellulaire. Bull Soc Méd Hôp Paris 1916;40:1462-70.
14. Hahn AF. The Guillain-Barré syndrome. Lancet 1998;352:635.
15. Caporale CM, Papola F, Fioroni MA, et al. Susceptibility of Guillain-Barré syndrome is associated to polymorphisms of CD1 genes. J Neuroimmunol 2006;177:112-8.
16. Li H, Yuan J, Hao H, Yan Z, Wang S. HLA alleles in patients with Guillain-Barré syndrome. Chin Med J (Engl) 2000;113:429-32.
17. Asbury AK, Cornblath DR. Assessment of current diagnostic criteria for Guillain-Barré syndrome. Ann Neurol 1990;27:S21- 4.
18. Agrawal S, Peake D, Whitehouse WP. Management of children with Guillain-Barré syndrome. Arch Dis Child Educ Pract 2007;92:161-8.
19. Haber P, DeStefano F, Angulo FJ, et al. Guillain-Barré syndrome following influenza vaccination. JAMA 2004;292:2478-81.
20. Ryan MM. Guillain-Barré syndrome in childhood. J Paediatr Child Health 2005;41:237-41.
21. Orange JS, Hossny EM, Weiler CR, et al. Use of intravenous immunoglobulin in human disease: a review of evidence by members of the Primary Immunodeficiency Committee of the American Academy of Allergy, Asthma and Immunology. J Allergy Clin Immunol 2006;117:S525-53.
22. Kessel A, Ammuri H, Peri R, et al. Intravenous immunoglobulin therapy affects T regulatory cells by increasing their suppressive function. J Immunol 2007;179:5571-5.
23. Susuki K, Atsumi M, Koga M, Hirata K, Yuki N. Acute facial diplegia and hyperreflexia: a Guillain-Barré syndrome variant. Neurology 2004;62:825-7.
24. Podnar S, Vodusek DB. Hyperreflexia in a patient with motor axonal Guillain-Barré syndrome. Eur J Neurol 2000;7:727-30.
25. Kuwabara S, Ogawara K, Koga M, Mori M, Hattori T, Yuki N. Hyperreflexia in Guillain-Barré syndrome: relation with acute motor axonal neuropathy and anti-GM1 antibody. J Neurol Neurosurg Psychiatry 1999;67:180-4.
26. Kuroki S, Saida T, Nukina M, et al. Campylobacter jejuni strains from patients with Guillain-Barré syndrome belong mostly to Penner serogroup 19 and contain beta-N-acetylglucosamine residues. Ann Neurol 1993;33:243-7.
27. Kuroki S, Haruta T, Yoshioka M, Kobayashi Y, Nukina M, Nakanishi H. Guillain-Barré syndrome associated with Campylobacter infection. Pediatr Infect Dis J 1991;10:149-51.
28. Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30:239-45.